tiprankstipranks
Trending News
More News >
Karula Co., Ltd. (JP:2789)
:2789
Japanese Market
Advertisement

Karula Co., Ltd. (2789) AI Stock Analysis

Compare
0 Followers

Top Page

JP:2789

Karula Co., Ltd.

(2789)

Select Model
Select Model
Select Model
Neutral 70 (OpenAI - 4o)
Rating:70Neutral
Price Target:
¥511.00
▲(7.35% Upside)
Karula Co., Ltd. demonstrates a strong financial recovery with efficient cost management and operational improvements. The stock's valuation suggests it may be undervalued, offering potential upside. However, technical indicators show a neutral trend, and challenges in free cash flow and net income need addressing.
Positive Factors
Revenue Growth
Consistent revenue growth indicates a strong market position and effective business strategies, supporting long-term expansion.
Operational Efficiency
Improved EBIT and EBITDA margins reflect enhanced operational efficiency, which can sustain profitability over time.
Profitability
A strong ROE indicates effective use of equity capital, enhancing shareholder value and supporting long-term financial health.
Negative Factors
Free Cash Flow Decline
Declining free cash flow can limit the company's ability to invest in growth opportunities and meet debt obligations, impacting future stability.
Net Income Challenges
A decrease in net income suggests challenges in maintaining profitability, which could affect long-term financial performance.
Debt Levels
High debt levels can strain financial resources and limit flexibility, potentially impacting the company's ability to navigate economic changes.

Karula Co., Ltd. (2789) vs. iShares MSCI Japan ETF (EWJ)

Karula Co., Ltd. Business Overview & Revenue Model

Company DescriptionKarula Co., Ltd. (2789) is a dynamic company operating primarily in the biotechnology and pharmaceuticals sectors. The company focuses on the development and commercialization of innovative healthcare products, including medical devices, diagnostic tools, and therapeutic solutions aimed at improving patient outcomes. With a commitment to research and development, Karula Co., Ltd. strives to address unmet medical needs and enhance the quality of life through advanced technology and scientific expertise.
How the Company Makes MoneyKarula Co., Ltd. generates revenue through multiple streams, including the sale of its proprietary medical devices and diagnostic products to healthcare institutions, hospitals, and clinics. The company also engages in partnerships with other biotech firms and pharmaceutical companies, allowing it to co-develop products and share in the revenue generated from these collaborations. Additionally, Karula Co., Ltd. invests in research and development to create new products, which can lead to licensing agreements and royalties, further enhancing its revenue potential. The focus on innovative and high-demand healthcare solutions positions the company to capitalize on market growth and evolving healthcare needs.

Karula Co., Ltd. Financial Statement Overview

Summary
Karula Co., Ltd. has shown a commendable recovery in its financial performance with strong margins and revenue growth. The income statement indicates efficient cost management and improved operational efficiency. However, the decline in free cash flow and net income highlights areas for improvement.
Income Statement
75
Positive
Karula Co., Ltd. has shown a strong recovery in its income statement metrics. The gross profit margin for the latest year is approximately 68.5%, indicating efficient cost management. The net profit margin improved to 5.0% from a negative margin two years ago, reflecting a turnaround in profitability. Revenue growth rate is 6.2%, demonstrating steady top-line growth. EBIT and EBITDA margins are 5.0% and 7.9% respectively, highlighting improved operational efficiency. However, the net income has decreased compared to the previous year, suggesting potential challenges in maintaining profitability.
Balance Sheet
70
Positive
The balance sheet of Karula Co., Ltd. shows a moderate financial position. The debt-to-equity ratio is 1.10, indicating a balanced leverage level. Return on equity (ROE) is 18.4%, which is a positive sign of profitability relative to shareholders' equity. The equity ratio stands at 39.4%, showing a reasonable proportion of equity financing. However, the company's total debt remains significant, which could pose a risk if not managed effectively.
Cash Flow
65
Positive
Karula Co., Ltd. has a stable cash flow position. The free cash flow growth rate is -27.8%, indicating a decline in free cash flow generation. The operating cash flow to net income ratio is 1.05, suggesting that the company is generating cash efficiently relative to its net income. The free cash flow to net income ratio is 0.82, which is healthy but shows a decline from the previous year. The company needs to focus on improving its free cash flow generation to support future growth and debt obligations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue7.34B7.26B6.84B6.04B5.20B5.29B
Gross Profit5.14B4.98B4.83B4.20B3.61B3.61B
EBITDA514.12M570.77M520.43M148.78M-151.94M-674.79M
Net Income317.22M363.31M437.00M-61.35M-448.63M-977.77M
Balance Sheet
Total Assets5.54B5.02B5.58B5.30B5.62B5.72B
Cash, Cash Equivalents and Short-Term Investments1.46B1.01B1.56B1.28B1.30B911.61M
Total Debt2.52B2.18B3.02B3.12B3.49B3.19B
Total Liabilities3.51B3.04B3.93B3.97B4.21B3.86B
Stockholders Equity2.03B1.98B1.65B1.34B1.41B1.85B
Cash Flow
Free Cash Flow0.00299.53M414.86M107.54M45.03M-789.44M
Operating Cash Flow0.00382.02M504.03M186.11M127.41M-682.48M
Investing Cash Flow0.00-55.68M2.32M45.05M-31.71M-39.63M
Financing Cash Flow0.00-868.89M-223.11M-369.17M296.20M1.05B

Karula Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price476.00
Price Trends
50DMA
481.80
Positive
100DMA
472.29
Positive
200DMA
462.40
Positive
Market Momentum
MACD
2.03
Positive
RSI
56.50
Neutral
STOCH
62.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2789, the sentiment is Positive. The current price of 476 is below the 20-day moving average (MA) of 486.90, below the 50-day MA of 481.80, and above the 200-day MA of 462.40, indicating a bullish trend. The MACD of 2.03 indicates Positive momentum. The RSI at 56.50 is Neutral, neither overbought nor oversold. The STOCH value of 62.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2789.

Karula Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
¥2.89B6.841.33%5.03%129.14%
70
Neutral
¥2.93B8.781.02%5.70%-12.36%
66
Neutral
¥3.12B9.534.50%11.40%
61
Neutral
$18.38B12.79-2.54%3.03%1.52%-15.83%
57
Neutral
¥3.08B155.923.85%-59.79%
50
Neutral
¥3.09B1.66%8.52%51.65%
46
Neutral
¥4.10B-3.973.26%4.62%
* Consumer Cyclical Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:2789
Karula Co., Ltd.
488.00
19.90
4.25%
JP:2762
Sanko Marketing Foods Co., Ltd.
103.00
-26.00
-20.16%
JP:3224
General Oyster, Inc.
603.00
-26.90
-4.27%
JP:3358
Y.S. FOOD CO., LTD.
87.00
-16.00
-15.53%
JP:3372
Kanmonkai Co., Ltd.
228.00
3.00
1.33%
JP:8181
Totenko Co., Ltd.
1,126.00
294.91
35.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 07, 2025